[go: up one dir, main page]

WO2017176199A1 - Composition de macronutriments à utiliser dans un procédé pour le traitement du diabète gestationnel - Google Patents

Composition de macronutriments à utiliser dans un procédé pour le traitement du diabète gestationnel Download PDF

Info

Publication number
WO2017176199A1
WO2017176199A1 PCT/SE2017/050334 SE2017050334W WO2017176199A1 WO 2017176199 A1 WO2017176199 A1 WO 2017176199A1 SE 2017050334 W SE2017050334 W SE 2017050334W WO 2017176199 A1 WO2017176199 A1 WO 2017176199A1
Authority
WO
WIPO (PCT)
Prior art keywords
macronutrient composition
meal
macronutrient
composition
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE2017/050334
Other languages
English (en)
Inventor
Gunnar Norstedt
Christer FRANZÉN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INDEVEX (PUBL) AB
Original Assignee
INDEVEX (PUBL) AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INDEVEX (PUBL) AB filed Critical INDEVEX (PUBL) AB
Publication of WO2017176199A1 publication Critical patent/WO2017176199A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention relates to a macronutrient composition for use in a method for treatment or prevention of gestational diabetes (GDM) in a subject.
  • GDM gestational diabetes
  • GDM gestational diabetes mellitus
  • GDM is a unique form of diabetes because it disappears after delivery of the baby. These different forms of diabetes are treated differently. Insulin is the mainstay of type I diabetes treatment, whereas type II diabetes can be pharmacologically treated with drugs that target cell metabolism (e.g. by metformin). In the case of type II diabetes, treatment usually begins with dietary advice and recommendations for increase of physical activity. GDM patients respond to either metformin or insulin but risks are associated with drug treatment and in the case of GDM one needs to be particularly concerned with potential effects on the developing child. It is clear that there are different forms of diabetes and that treatments of these different forms need to be adapted to the specific type of diabetes.
  • GDM there is a lack of effective and harmless treatment.
  • GDM recommendations i.e. recommendations on what to eat or not, in contrast to type II diabetic subjects for which recommendations regarding food types are commonly given.
  • Hernandez, T.L. et al. presents a research overview regarding nutritional management of GDM, i.e. the use of diet for prevention and treatment of GDM.
  • a main conclusion of this research overview is that no particular diet has shown to have any significant effect on prevention or treatment of GDM.
  • drug treatments are used in the form of insulin or metformin but there is no generally accepted drug treatment for GDM.
  • a purpose of the invention is to provide effective and safe treatment and prevention of GDM using a macronutrient composition.
  • the invention concerns a macronutrient composition for use in a method for treatment or prevention of gestational diabetes in a subject, wherein the macronutrient composition is administrated with a time period between administration and a meal ranging from 240 - 15 minutes before said meal, more preferably 60-30 minutes before said meal, wherein the macronutrient composition is administrated orally to the subject at least before one daily meal, preferably before each meal, and wherein the macronutrient composition comprises proteins in the range of 20-60 g/lOOg macronutrient composition, lipids in the range of 5-20 g/100 g macronutrient composition and carbohydrate in the range of 10-50g /100g macronutrient composition.
  • the invention also concerns a method of treating or preventing gestational diabetes comprising administering an effective amount of a macronutrient composition to a subject suffering from or posing a particular risk of developing gestational diabetes.
  • the invention also concerns a use of a macronutrient composition in a method for treatment or prevention of gestational diabetes in a subject.
  • the macronutrient composition may be consumed in various amounts and intake frequencies and still provide for an advantageous effect, the invention focuses on the concept of pre-meal where a small amount of nutrients, typically around 15-20 g, is consumed in addition to standard meals and preferably before each meal. This concept is different from frequency of food intake, which often is referred to in connection with treatment of type II diabetes.
  • the macronutrient composition can be consumed three times a day in addition to regular meals, but without specifying exactly how long before a meal the macronutrient composition should be consumed. Preferably, the three occasions when the macronutrient composition is consumed are reasonably evenly distributed over the day.
  • administration time between intake of the macronutrient composition and a meal ranges from 240 - 15 minutes before each meal, preferably 120-20 minutes before each meal, more preferably 60-30 minutes before each meal and most preferably around 30 minutes before each meal.
  • the macronutrient composition the pre-meal, activates the gastro-intestinal (incretin) system and places the phase of satiety at an earlier time point without adding excessive energy. It also supports the maintenance of balanced post prandial blood glucose levels, being of particular importance to the GDM patient.
  • the macronutrient composition for treating GDM can be used for preventing GDM by administering the composition to a subject posing a particular risk of developing GDM. Typically, this would be a mother who has experienced GDM during a previous pregnancy and thus has an increased risk of GDM in her next pregnancy.
  • the macronutrient composition, method and use according to the invention thus provides for effective and safe treatment and prevention of GDM.
  • GDM gestational diabetes
  • Type I is most likely caused by immune-mediated destruction of beta cells whereas Type II relates to insensitivity to insulin.
  • Gestational diabetes is unique in that it (1) is reversible (disappears after delivery) and (2) is related to the presence of a placenta and the metabolic adaptations to pregnancy. Furthermore, the diagnosis of gestational diabetes has specific and different diagnostic criteria compared to type II diabetes. The placenta (unique to pregnancy) produces several hormones leading to changes in body metabolism and insulin sensitivity. The situation that GDM is unique from type II diabetes can further be related to specific gene functions.
  • One example (in animals) concern elimination of the prolactin (Prl) receptor in pancreatic beta cells.
  • Micronutrients are a class of chemical compounds which humans consume in the largest quantities (must be above a threshold amount) and which provide humans with the bulk of energy. There are three primary macronutrients: proteins, fat, and carbohydrates.
  • macronutrients are herein defined as proteins, fats, and carbohydrates.
  • the macronutrient composition comprises at least proteins, fats, and carbohydrates.
  • the method comprises administering the macronutrient composition with a time period between administration of the macronutrient composition, the pre-meal, and meal is ranging from 240 - 15 minutes before each meal, more preferably 60-30 minutes before each meal and most preferably 30 minutes before each meal.
  • a meal is herein meant to be a meal having an energy content of at least 1/5 of the recommended daily intake for the actual consumer group, i.e. approximately 400 kcal. In an embodiment, the meal has an energy content of at least 300 kcal.
  • pre-meal treatment can be to reduce food intake as well as reduce the need for snacking in between meals.
  • Pre-meal treatment leads to a significantly higher postprandial satiety at the onset of the following meal (at time point 0 min, e.g. 30 minutes after pre-meal was given) which reduces meal size and attenuate the following blood sugar response.
  • the levels of post-prandial blood glucose (2h-BG) and HbAlc are reduced over time with the consistent use of the pre-meal concept.
  • a macronutrient composition used as a pre-meal to treat GDM is likely to affect other components e.g. cholesterol and LDL concentrations as well as CRP, a marker of chronic low grade inflammation.
  • the macronutrient composition is administrated orally to the subject at least before one daily meal, preferably before each meal. This will keep the blood sugar levels post meal at a desired level.
  • the macronutrient composition is administrated before each meal over a period of time.
  • the effect of pre-meal is better if the subject consequently uses pre-meal before each meal, every day, over a period of time. This will provide the subject with consistent long-term benefits.
  • the time period during which the macronutrient composition is given may be at least from the day the GDM diagnosis is confirmed, typically between 12 th to 18 th week of pregnancy and on- going until the day of birth.
  • the macronutrient composition may also well be given as a prevention diet already at the early days of the confirmed pregnancy. If a patient has one or more risk factors for GDM, treatment with the macronutrient composition can begin already before the conception.
  • the macronutrient composition comprises proteins in the range of 20-60 g/lOOg, lipids in the range of 5-20 g/100 g and carbohydrate in the range of 10-50g /100g, as a weigh percent of the total weight of the macronutrient composition.
  • the macronutrient composition comprises 20-60 weight-% proteins, 5-20 weight-% lipids and 10-50 weight-% carbohydrates.
  • the macronutrient composition comprises egg(s), whey, pea protein and rosaceous plants, such as rose hip and/or apple(s).
  • the macronutrient composition comprises pea, whey, chicken egg, rosaceous plants and sugar beet fiber, egg albumin, milk, and eventual flavour, sweetener and colour.
  • the macronutrient ingredients are preferably in dry powder form.
  • the macronutrient composition is formulated as a dry powder.
  • the macronutrient composition is characterized by a low glycemic index.
  • a low glycemic index (Gl) is defined as below 55 following internationally accepted technology for measurement. A low-GI food will release glucose more slowly and steadily, which leads to more suitable postprandial (after meal) blood glucose readings. It is also preferred that the macronutrient composition has a low the glycemic load (GL), below 10 following internationally accepted standard calculation.
  • the macronutrient composition is dissolved in water, other liquids or semi liquids and administrated as a pre-meal drink.
  • the macronutrient composition is formulated to provide an energy value ranging between 60 - 200 kcal, more preferably 70 - 130 kcal/g.
  • the macronutrient composition further comprises micro nutrients and/or trace elements as natural constituents.
  • the macronutrient composition is enriched with micro nutrients and/or trace elements.
  • the macronutrient composition is administered in an amount of 10-30 g, preferably 12-25 g, more preferably 14-20 g per serving.
  • the amount per serving of the macronutrient composition is ca 18 g.
  • Such a serving can include 7.5 g protein, 1.5 g fat (a mix of saturated and unsaturated fat), 1 g fiber and 4 g carbohydrates, which provides approximately 70 kcal energy. It can also include around 1 g of micronutrients (minerals and vitamins) and water.
  • the gestational diabetes is defined as elevated fasting glucose values or pathological test results following an oral glucose tolerance tests or standardized meals.
  • subjects with gestational diabetes are treated with the macronutrient composition.
  • subjects at risk to develop gestational diabetes are treated with the macronutrient composition.
  • the efficacy of the macro-nutrient pre-meal method is monitored by measurements of glucose, insulin, GLP-1 and/or GLP-2.
  • the blend of nutrients in the pre-meal ideally includes proteins from different sources since the kinetics and bioavailability differs as well as the amino acid profile.
  • Whey protein is the fastest (impact on insulin release) and pea protein is probably the most satiating. Fibers in the pre-meal also stimulate the feeling of satiety, as well as a feeling of fullness in the stomach.
  • the pre-meal also has a low Glycemic Index and contain few calories. Since users are likely to reduce their meal sizes it is an advantage that the pre-meal mix has a high content of essential nutrients including all essential amino acids and Omega 3 and 6 fatty acids in a preferred balance.
  • pre-meal is used for the macronutrient composition of the invention
  • pre-meal concept is used for the macronutrient composition of the invention being administrated at a predetermined time prior to a meal.
  • the invention also concerns a method of treating gestational diabetes comprising administering an effective amount of a macronutrient composition to a subject suffering from gestational diabetes.
  • the method comprises administering the macronutrient composition with a time period between the administration of the macronutrient composition, the pre-meal, and a meal ranging from 240 - 15 minutes before each meal, more preferably 60-30 minutes before each main meal. This time range allows the macronutrient composition to achieve the optimal effect on satiety and attenuate the following blood sugar response.
  • the method of treating or preventing gestational diabetes comprises administering an effective amount of a macronutrient composition to a subject suffering from or posing a particular risk of developing gestational diabetes.
  • the method comprises administrating the macronutrient composition orally to the subject at least before one daily meal, preferably before each meal.
  • gestational diabetes is being defined as elevated fasting glucose values or pathological test results following an oral glucose tolerance tests or standardized meals.
  • the method comprises measuring levels of certain components in blood, wherein the components are chosen from the group including GLP-1, GLP-2, insulin, HblAC, fatty acid and cholesterol containing components, such as to monitor the effect of the treatment.
  • the administration scheme of the pre-meal may be determined based on the levels measured.
  • the method comprises the step of dissolving the macronutrient composition in water, other liquids or semi liquids and administrating the macronutrient composition as a pre-meal drink.
  • the method may comprise preparing a macronutrient composition comprising eggs, whey, pea protein and rosaceous plants in dry powder form.
  • the invention also concerns the use of a macronutrient composition in a method for treatment or prevention of gestational diabetes in a subject.
  • Figure 1 exemplifies pre-meal concept used in treatment of GDM.
  • the present inventors have found that patients with gestational diabetes react significantly to a method of treatment using the pre-meal concept, i.e. eating a macronutrient composition prior to a meal.
  • the pre-meal macronutrient composition used consisted of a mix of high quality macronutrients given to patients 30 min before each meal.
  • the ingestion of a low calorie composition of macronutrients with a low glycaemic index before regular meals resulted in an improvement of the metabolic situation for women with diagnosed gestational diabetes (GDM).
  • Gestational diabetes is usually diagnosed relatively late during pregnancy.
  • Figure 1 shows a time line of the first 1, second 2 and third 3 trimester of a pregnancy.
  • the schematic Figure 1 indicates a time point 4 of GDM diagnosis; second trimester.
  • Point 5 indicates the beginning of the pregnancy.
  • Pre-meal treatment is initiated and the treatment goes on until delivery.
  • the Pre-meal concept involves the intake of a defined macronutrient composition before each regular meal; breakfast 6, lunch 7 and dinner 8, shown on the lower bar that represents one day.
  • a suitable pre-meal schedule during one day is illustrated in the lower bar: arrows represent the pre-meal 30 minutes before breakfast 6, lunch 7 and dinner 8.
  • pre-meal treatment can begin already at the start of or before pregnancy 5 and go on throughout the entire pregnancy. This is suitable if the woman has suffered from GDM during a previous pregnancy.
  • Example 1 Example of a macro nutrient composition that can be used to practice the present invention
  • Indevex Nutrientshake is a commercially available dry powder formulation (Indevex AB (publ), Sweden; www.indevex.com).
  • the Indevex Nutrientshake is based on NGC Premix consisting of natural macronutrient whole food ingredients (pea, whey, chicken egg, rosaceous plants and sugar beet fiber), egg albumin, milk, and eventual flavour, sweetener and colour.
  • Indevex Nutrientshake comprises proteins from whey (milk), egg and peas. The three sources of protein covers approximately 1/3 of the body's daily need for all essential amino acids (Indevex Nutrientshake has a high amino acid score according to WHO criteria) which is important in building and maintaining muscle mass.
  • Indevex Nutrientshake contains carbohydrates that are slowly digested. Indevex Nutrientshake contains the two important essential fatty acids, Omega 3 and 6, both polyunsaturated fatty acids (PUFAs). These contain linoleic acid (LA) and alpha-linoleic acid (ALA), widely distributed in plant oils.
  • LA linoleic acid
  • ALA alpha-linoleic acid
  • the human body has a limited ability to convert ALA into the longer-chain Omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which also can be obtained from fish.
  • EPA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • the balance between Omega 3 and 6 is vital for health.
  • the Omega 3 and 6 fatty acids ratio present in the product is within the ratio 1:2 - 1:4. Rosaceous plants are naturally rich in vitamins, especially vitamin C which is an important antioxidant.
  • Indevex Nutrientshake contains both water-soluble and water-insoluble dietary fibres.
  • the composition comprises fat, carbohydrates, proteins, vitamins and minerals, wherein the carbohydrates are derived from foodstuffs having a low glycemic index; and wherein the macronutrient composition comprises fat, carbohydrates, proteins, vitamins and minerals present in the form of 10-20% whole eggs, 10-25% whey, 15-30% yellow peas, 4- 15% egg albumen and 15-40% rosaceous plants, each as a weight percent of the macronutrient composition.
  • a serving of Indevex Nutrientshake in the form of a dry powder mix shake product (18 grams) includes 15 grams of the NGC Premix ingredient, including and providing approximately 7.5 g protein, 1.5 g fat (a mix of saturated and unsaturated fat), 1 g fiber and 4 g carbohydrates, which provides approximately 70 kcal energy.
  • the 15 g of NGC Premix includes also around 1 g of micronutrients (minerals and vitamins) and water.
  • a serving of Indevex Nutrientshake contains ingredients added to improve taste.
  • the dry powder is intended to be mixed by shaking with 150 ml cold drinking water (and this was done in the experiments described in this document).
  • the GL value of this pre-meal macronutrient composition is less than 10.
  • a macronutrient composition mix is given in detail herein.
  • Other macronutrient compositions that also fulfil e.g. low calorie and low glycemic index requirements, preferably a Gl below 55, may alternatively be used.
  • OGTT oral glucose tolerance test
  • the pre-meal concept treatment administrating the macronutrient composition to the patient prior to meals, will begin at the first instance following the diagnosis of GDM 4.
  • the recommended treatment schedule will be approximately 30 minutes before each meal i.e. a macronutrient pre-meal before breakfast 6, lunch 7 and dinner 8.
  • the pre-meal concept treatment will begin when pregnancy has first been identified 5 and this is of particular relevance for patients with an elevated GDM risk e.g. those who have previously had GDM.
  • OGTT oral glucose tolerance tests
  • a patient was tested using a standardized oral glucose tolerance tests (OGTT) by drinking 200 ml water containing 75 g glucose, i.e. a glucose solution. Insulin was measured using a radioimmunoassay in blood samples obtained at the time points indicated. OGTT was carried out in the morning before breakfast and was first carried out without pre-meal, four days later OGTT was repeated with pre-meal (Indevex Nutrientshake). The control situation consisted of 200 ml of water. It can be observed that pre-meal treatment given 30 minutes before the OGTT increased levels of insulin.
  • the pre-meal macronutrient composition used was Indevex Nutrientshake as described in Example 1. In similar procedures one can use other read-outs, e.g. GLP-1 to monitor the biological activity of pre-meal treatments.
  • Example 4 Effect of a macronutrient pre-meal in gestational diabetes.
  • a first group the Treatment group, received pre-meal concept treatment using the composition described in Example 1.
  • a second group, the Control group received comparative pre-meal treatment based on milk powder and having a similar caloric content as the pre-meal of the Treatment group.
  • the pre-meals were given to patients 30 min before each meal. The treatment was continued for nine weeks (average 65 days) until delivery. Levels of fasting blood glucose and two-hour postprandial blood glucose (two hours after a standardized meal) were determined before starting the treatment as well as after treatment (after nine weeks). The results are shown in Table 2.
  • pre-meal concept treatment significantly improved glucose tolerance following a standardized meal in the Treatment group. This follows from the observation that the macro-nutrient pre-meal treatment significantly reduced the 2h post prandial glucose level compared to the level before treatment (the mean value was reduced from 9.25 to 6.06). The corresponding level for the Control group might also have been somewhat reduced (from 8.86 to 7.12) but this difference is not significant.
  • the experiment demonstrates that the macronutrient pre-meal treatment is beneficial for the control of postprandial blood glucose in patients with gestational diabetes.
  • Patients hospital days, differences of delivery mode and birth weight were also compared.
  • the fasting blood sugar and 2 hour postprandial sugar before delivery was significantly lower in the intervention/treatment group, p ⁇ 0,05.
  • the time for delivery and birth weight was not different between the groups.
  • the study suggests that macronutrient pre-meal treatments can be routinely used in patients with gestational diabetes as a valuable nutritional intervention.
  • Example 5 In this example a typical patient is described that is treated with the pre-meal concept.
  • a woman age 32 was found to have a fasting blood sugar value of 8 mmol/l that was detected on two different occasions, when subjected to the standard oral glucose tolerance test her 2h value was 10 mmol/l.
  • GDM gestational diabetes mellitus
  • the patient was referred to a maternal care unit, specialized in the care of GDM.
  • the patient was found to be pregnant in the late second trimester, slightly over weight and had a normal blood pressure. The pregnancy was found to proceed normally and there were no signs of any other pathologies than GDM.
  • the patient did not report any allergies or intolerance to lactate or gluten.
  • the patient was given life style advice consisting of dietary recommendation and encouragement of increased physical activity.
  • the patient was also instructed to adhere to the pre-meal concept and she was given a pre-meal composition as described in Example 1 to be taken three times per day, 30 minutes before each meal until the time of delivery. Repeated check-ups of the patients found near to normal blood glucose values and she delivered a normal baby within the predicted time for delivery.
  • Example 6 In this example a typical patient is described that is treated with the pre-meal concept.
  • GDM gestational diabetes
  • She blood sugar was found to within the normal range and this was also the case with the oral glucose tolerance test. She has no other symptoms of disease and did not report any past disorders with the exception of GDM, she was not allergic, nor lactate or gluten intolerant. Because of the increased risk to develop GDM she was given pre-meal treatment as in Example 5. Evaluation of her health status showed that she did not develop GDM and that she later gave birth to a normal child.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pediatric Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition de macronutriments à utiliser dans un procédé pour le traitement ou la prévention du diabète gestationnel chez un sujet et un procédé de traitement du diabète gestationnel consistant à administrer une quantité efficace d'une composition de macronutriments à un sujet souffrant de diabète gestationnel ou présentant un risque particulier de développer un diabète gestationnel.
PCT/SE2017/050334 2016-04-05 2017-04-04 Composition de macronutriments à utiliser dans un procédé pour le traitement du diabète gestationnel Ceased WO2017176199A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1650462A SE1650462A1 (en) 2016-04-05 2016-04-05 A macronutrient composition for use in a method for treatment of gestational diabetes
SE1650462-3 2016-04-05

Publications (1)

Publication Number Publication Date
WO2017176199A1 true WO2017176199A1 (fr) 2017-10-12

Family

ID=60000757

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2017/050334 Ceased WO2017176199A1 (fr) 2016-04-05 2017-04-04 Composition de macronutriments à utiliser dans un procédé pour le traitement du diabète gestationnel

Country Status (2)

Country Link
SE (1) SE1650462A1 (fr)
WO (1) WO2017176199A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111000223A (zh) * 2019-12-17 2020-04-14 北京惠爱惠远国际健康管理有限公司 妊娠糖尿病孕中晚期控糖营养餐制备方法
CN112890177A (zh) * 2021-02-24 2021-06-04 云南屯屯麦生物技术研究有限公司 一种用于降低妊娠期餐后血糖水平的组合物及其制备方法
EP3809880A4 (fr) * 2018-06-22 2022-03-23 Fonterra Co-Operative Group Limited Utilisation de lipides polaires pour traiter ou prévenir le diabète sucré gestationnel

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2011506A1 (fr) * 2007-07-05 2009-01-07 Nestec S.A. Supplémentation de régime maternel
WO2016020489A1 (fr) * 2014-08-08 2016-02-11 Nestec S.A. Vitamine b2 pour diabète gestationnel

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2011506A1 (fr) * 2007-07-05 2009-01-07 Nestec S.A. Supplémentation de régime maternel
WO2016020489A1 (fr) * 2014-08-08 2016-02-11 Nestec S.A. Vitamine b2 pour diabète gestationnel

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CRISTINA MORENO-CASTILLA ET AL.: "Role of medical nutrition therapy in management of gestational diabetes mellitus", CURRENT DIABETES REPORTS, vol. 16, no. 22, 2016, pages 1 - 9, XP035949991 *
HERNANDEZ, T. L. ET AL.: "Strategies in the Nutritional Management of Gestational Diabetes", CLIN. OBSTET. GYNECOL., vol. 56, 2013, pages 803 - 815, XP055429749 *
LI LI ET AL.: "Effect of a macronutrients preload on blood glucose level and pregnancy outcome in gestational diabetes", JOURNAL OF CLINICAL & TRANSLATIONAL ENDOCRINOLOGY, vol. 5, 2016, pages 3 6 - 41, XP055429719 *
LI LI ET AL.: "Effect of diabetes-specific pre-meal nutrition powder on blood glucose level and pregnancy outcome of gestational diabetes", DIETARY FIBER AND HEALTH - THE PROCEEDINGS OF THE 17TH ANNUAL CONFERENCE OF THE DANONE NUTRITION CENTER, 7 November 2014 (2014-11-07), Retrieved from the Internet <URL:http://cnki.sris.com.tw/KCMS/detail/detail.aspx?filename=DNZX201411002034&dbcode=CPFD&dbname=CPFD2015> *
LI, C. J. ET AL.: "Effects of a macro-nutrient preload on type 2 diabetic patients", FRONT. ENDOCRINOL, vol. 6, 2015, XP055429743 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3809880A4 (fr) * 2018-06-22 2022-03-23 Fonterra Co-Operative Group Limited Utilisation de lipides polaires pour traiter ou prévenir le diabète sucré gestationnel
US12465619B2 (en) 2018-06-22 2025-11-11 Fonterra Co-Operative Group Limited Use of polar lipids to treat or prevent gestational diabetes mellitus
CN111000223A (zh) * 2019-12-17 2020-04-14 北京惠爱惠远国际健康管理有限公司 妊娠糖尿病孕中晚期控糖营养餐制备方法
CN112890177A (zh) * 2021-02-24 2021-06-04 云南屯屯麦生物技术研究有限公司 一种用于降低妊娠期餐后血糖水平的组合物及其制备方法

Also Published As

Publication number Publication date
SE1650462A1 (en) 2017-10-06

Similar Documents

Publication Publication Date Title
CN102065699A (zh) 含脂质组合物及其使用方法
TW201036618A (en) Nutritional composition for controlling blood sugar level
US20040265360A1 (en) Ingestible composition
EP3010357B1 (fr) Administration d&#39;un produit de type composition alimentaire
WO2017176199A1 (fr) Composition de macronutriments à utiliser dans un procédé pour le traitement du diabète gestationnel
EP2645878A1 (fr) Prévention ou traitement du surpoids et de l&#39;obésité chez des patients atteints d&#39;un diabète de type 2
WO2015009225A1 (fr) Produit à base d&#39;une composition alimentaire
Jones Diabetes: The problem of sugar in the blood...
Lapolla et al. Medical nutrition therapy in physiological pregnancy and in pregnancy complicated by obesity and/or diabetes: SID-AMD recommendations
RU2714315C1 (ru) Способ метаболической коррекции у пациентов с белково-энергетической недостаточностью (БЭН)
Depauw et al. Supportive nutrition for elderly chimpanzees: a case study on non-invasive supplementation in a group setting
Bais Text Book Of Biochemistry (For Nursing Students)
Marks et al. The Cambridge Diet: A Manual for Practitioners
Chaney et al. Nursing care of conditions related to the endocrine system
Barnard et al. Vegan Diets for Diabetes Prevention and Management of Cardiometabolic Risk
US20240138458A1 (en) Protein food composition having ultra-low calories and high bioabsorption rate and method for providing diet information using same
Mann Diabetes and the Metabolic Syndrome
JP6847114B2 (ja) ３’−ｏ−メチル−４’−ｏ−サルフェートエピカテキンを含む組成物及びかかる組成物の治療的使用
Ilhomovich Diagnosis Of Non-alcoholic Fatty Liver Disease And Its Prevention
Saunders et al. Nutritional Aspects of Gestation and Puerperium
Tumram et al. A CONCISE REVIEW ON VIRUDDHA AHARA AS A CAUSE OF LIFESTYLE DISORDERS
Axen et al. Nutritional issues in the frail older person
Bellow et al. Diabetes: nutrition and health
Escott-Stump THEME THREE Homeostasis and Regulation
Rubino et al. Advances in infant nutrition.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17779442

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17779442

Country of ref document: EP

Kind code of ref document: A1